KMT2C mutation	Colorectal Cancer	KMT2C mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Solid Tumor	KMT2C mutation	Solid Tumor	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Non Small Cell Lung Cancer	KMT2C mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Hepatocellular Cancer	KMT2C mutation	Hepatocellular Cancer	PD1 inhibitor + lenvatinib Sensitive: C3 – Early Trials PD1 inhibitor + lenvatinib Sensitive : C3	PD1 inhibitor + lenvatinib Sensitive: C3 – Early Trials PD1 inhibitor + lenvatinib Sensitive : C3
KMT2C mutation	Renal Cell Carcinoma	KMT2C mutation	Renal Cell Carcinoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Melanoma	KMT2C mutation	Melanoma	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KMT2C mutation	Bladder Cancer	KMT2C mutation	Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3

KMT2C mutation

Associations